Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.
Alpine Immune Sciences has raised $150.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in November 2023.
Alpine Immune Sciences's investors include TCG Crossover, Samsara BioCapital, OrbiMed, Decheng Capital, Omega Funds.
Alpine Immune Sciences is headquartered in Seattle, United States.
Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.
Alpine Immune Sciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alpine Immune Sciences — Funding & Investors." VCBacked, November 6, 2023, https://www.vcbacked.co/company/alpine-immune-sciences. Accessed November 12, 2026.
VCBacked. (2023). Alpine Immune Sciences — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/alpine-immune-sciences
{{cite web |title=Alpine Immune Sciences — Funding & Investors |url=https://www.vcbacked.co/company/alpine-immune-sciences |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Alpine Immune Sciences? Request a listing update